Market News

Kintara Therapeutics Shares (NASDAQ: KTRA) Surge after Receiving Fast Track Designation

Shares of Kintara Therapeutics (NASDAQ: KTRA) jumped as much as 30% in today’s trading session. This can be attributed to the news of a fast track designation granted to the company by the FDA for its breast cancer candidate.

This will allow Kintara’s treatment to reach patients sooner if it were to eventually get approved. The stock has since given up a large chunk of its gains but still maintains a 12% gain on the day.

Is Kintara Stock a Buy?

Kintara stock has a Hold consensus rating based on two Holds assigned in the past three months. Interestingly, these analysts haven’t assigned a price target, implying that the stock is too unpredictable.


Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More